RNS Number : 3253Y MaxCyte, Inc. 02 January 2024 MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director ROCKVILLE, MD , January 2, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
RNS Number : 1118Y MaxCyte, Inc. 29 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 29, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4671W MaxCyte, Inc. 12 December 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 MaxCyte Announces CEO
Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating
RNS Number : 0411W MaxCyte, Inc. 07 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 7, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4853V MaxCyte, Inc. 04 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 4, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
ROCKVILLE, Maryland - 1 December 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announcesthat pursuant to its block admission facility, since 31 October 2023 it has issued133,442of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.
ROCKVILLE, MD, November 30, 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 27 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, aNon-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
ROCKVILLE, MD, November 17, 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 14 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, aNon-Executive Director of the Company, exercised options over 10,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines ROCKVILLE, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
